WALTHAM, MA -- April 18, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, has developed two new luminescent gene reporter assays kits, steadylite plus™ and britelite™ plus, which deliver industry-leading speed and sensitivity in new conveniently-stored, odor-free formulations.

“The new steadylite plus and britelite plus offer high-throughput screening laboratories the same performance and reliability of our current luminescent reporter gene reagents, and are further proof of our continued commitment to developing our reagent tool box for GPCR research,” says Dr. Richard Eglen, vice president and general manager, Discovery & Research Reagents, for PerkinElmer Life and Analytical Sciences. “These new kits can be conveniently stored at refrigerated temperatures instead of freezer temperatures so they can be used right away without thawing and our odor-free reagents eliminate the need for working in hoods.”

steadylite plus and britelite plus are highly sensitive firefly luciferase reporter gene assay kits for the quantification of gene expression in cells. Cell-based assays, especially for high value GPCR targets, are increasingly critical to pharmaceutical drug discovery screening.

With its long-lasting signal, steadylite plus is designed for batch-processing systems. britelite plus is designed for continuous process systems. Both steadylite plus and britelite plus kits are suitable for high-density microplates such as 384- and 1536-well plates in high throughput environments. steadylite plus can also be used for smaller-scale sample analysis in 96-well plates when higher sensitivity is required.

PerkinElmer’s portfolio of luciferase-based assays with a broad dynamic range feature optimized reagents for highly specific HTS screens. In addition to reporter gene assays, PerkinElmer offers ATPlite™ cytotoxicity/cell proliferation assays and easylite™ kinase assays. steadylite plus and britelite plus assay kits are compatible with the leading luminescent detection instruments including PerkinElmer’s high-performance ViewLux™, EnVision™, Fusion™, and TopCount® readers.

For more information on britelite plus and steadylite plus or other luciferase-based assays or luminescent technologies, visit PerkinElmer online at www.perkinelmer.com or contact a PerkinElmer sales representative.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.